South Dakota: Market and legal data for the cannabis sector

6th November 2024: US - South Dakota: South Dakota voters rejected measure 29, which would have legalised recreational cannabis in the state, with 57% casting ballots in opposition. The 2024 election marks South Dakota’s third attempt to legalise adult-use cannabis. With measure 29’s failure, the state will remain a medical cannabis-only state.
5th November 2024: US - Federal: Today, voters in Florida, North Dakota and South Dakota will vote on ballot initiatives to legalise recreational cannabis in their states while those in Nebraska will vote on medical cannabis measures. The election represents the third time that voters in both North Dakota and South Dakota will decide on this issue. Meanwhile, in Nebraska, voters will vote on a pair of measures that would legalise medical cannabis and establish regulations for the industry.
4th June 2024: US - South Dakota: The Secretary of State has verified enough signatures for a ballot measure that would legalise recreational cannabis in the state to reach the November ballot, press reports. The same advocates behind this measure put initiatives on the ballot twice before, once in 2020 – which was approved by voters but later overturned by the courts – and again in 2022, when voters rejected it. If approved, the measure would allow for the possession, use and transportation of cannabis by adults (21+), and allow adults to cultivate up to six plants in their homes.
9th May 2024: US - South Dakota: Advocates have turned in more than 29,000 signatures to place an initiative on the November 2024 ballot to legalise recreational cannabis, press reports. The secretary of state must now verify that there are at least 17,508 valid signatures for it to reach the ballot. The same advocates put initiatives on the ballot twice before, once in 2020 – which was approved by voters but later overturned by the courts – and again in 2022, when voters rejected it. Advocates hope that higher voter turnout in a presidential election year could lead to results more similar to 2020 than 2022.
27th March 2024: US - South Dakota: House Bill (HB) 1125 has been signed by the governor. HB 1125 will prohibit "chemically derived cannabinoids" – which are psychoactive cannabinoids that are changed molecularly through a chemical process (not to include decarboxylation) – from being produced or sold in the state. It will be unlawful to chemically modify or convert industrial hemp, or engage in any process that converts cannabidiol, into delta-8 THC, delta-9 THC, delta-10 THC, or any other tetrahydrocannabinol isomer, analogue, or derivative.
20th March 2024: US - South Dakota: Senate Bill (SB) 43 has been signed by the governor. SB 43 will make minor amendments to the state’s medical cannabis programme by requiring the Department of Health to establish certain penalties for violation of medical cannabis regulation and increasing the maximum amount that the department can charge for registration certificates.
8th March 2024: US - South Dakota: Senate Bill (SB) 117 has been signed by the governor. SB 117 will exclude “industrial hemp stalk bale” from certain requirements and extend the validity of a hemp processor licence to three years.
7th March 2024: US - South Dakota: Senate Bill (SB) 42 has been signed by the governor. SB 42 will make various amendments to the state’s medical cannabis programme, including changes to testing requirements, the allowable amount of medical cannabis that can be dispensed to qualified patients, and the procedure for violations of medical cannabis regulations.
27th February 2024: US - South Dakota: Senate Bill (SB) 117 has been passed by both chambers (the Senate and the House) and now heads to the governor. SB 117 would exclude “industrial hemp stalk bale” from certain requirements and extend the validity of a hemp processor licence to three years.
27th February 2024: US - South Dakota: House Bill (HB) 1125 has been passed by the Senate. As the Senate amended the previously passed House version, the bill must be reconciled before being sent to the governor. HB 1125 would prohibit “chemically derived cannabinoids” – which are psychoactive cannabinoids that are changed molecularly through a chemical process (not including decarboxylation) – from being produced or sold in the state. The Senate has amended the bill to include that it would be unlawful to chemically modify or convert industrial hemp, or engage in any process that converts cannabidiol into delta-8 THC, delta-9 THC, delta-10 THC or any other THC isomer, analogue or derivative.
27th February 2024: US - South Dakota: Senate Bill (SB) 43 has been passed by the House and now heads to the governor’s desk. SB 43 would make minor amendments to the state's medical cannabis programme by requiring the department of health to establish certain penalties for violations of medical cannabis regulations and increasing the maximum amount that the department may charge for registration certificates.
23rd February 2024: US - South Dakota: Senate Bill (SB) 42 has been passed by the House and now heads to the governor’s desk. SB42 would make various amendments to the state’s medical cannabis programme. Amendments include changes to testing requirements, the allowable amount of medical cannabis that can be dispensed to qualified patients, and the procedure for violations of the medical cannabis regulations.

LATEST ALERTS

Cannabis and cannabinoids in South Dakota

Future looks promising for US state-level legalisation despite midterm setback

Coming together over cannabis: is support becoming a bipartisan issue?

South Dakota in the US passes legislation making delta-8 THC legal for adult use

2022 US cannabis ballot initiative tracker

Which US states allow the sale of intoxicating hemp-derived cannabinoids in dispensaries?

US regulatory trends on intoxicating hemp-derived cannabinoids

US regulatory tracker: state regulation of delta-8 THC, October

US regulatory tracker: proposed state laws, October

Sign up to our newsletter

LATEST ALERTS

Cannabis and cannabinoids in South Dakota

Sign up to our newsletter

Start your FREE trial